Takeda Agrees to Pay $13.6M to Resolve False Claims Act Kickback Allegations

Takeda Pharmaceuticals U.S.A., Inc. has agreed to pay approximately $13.6 million to resolve allegations that it violated the False Claims Act and Anti-Kickback Statute by providing improper payments and benefits to healthcare providers to encourage prescriptions of the antidepressant Trintellix. According to the Department of Justice, federal investigators alleged that Takeda used paid speaker programs, honoraria, and high-end meals to improperly influence physicians’ prescribing decisions involving federal healthcare beneficiaries.

The government alleged that, between 2014 and 2020, Takeda selected physicians for speaker programs with the intent of increasing Trintellix prescriptions reimbursed by Medicare and other federal healthcare programs. Prosecutors also contended that some healthcare providers attended multiple programs on the same topic and received repeated meals and payments despite little or no legitimate educational benefit. Federal authorities stated that the alleged conduct undermined the independence of medical decision-making and resulted in false claims being submitted to government healthcare programs.

The settlement reflects continued federal scrutiny of pharmaceutical company relationships with prescribing physicians and the government’s aggressive enforcement of healthcare fraud laws involving kickbacks and improper financial incentives. Cases like this also highlight the important role that whistleblowers and qui tam actions can play in identifying potentially unlawful conduct involving federal healthcare programs and taxpayer funds.